Over 40% of Adults Struggle to Swallow Pills - BioNxt Targets a Global Adherence Problem with Rapid-Dissolving Thin-Film “Melt-in-Your-Mouth” Therapies

VANCOUVER, BC / ACCESS Newswire / December 17, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce significant progress in its mission to address one of the most overlooked barriers in medicine: swallowing difficulties (dysphagia). Surveys suggest that up to 40% of adults have experienced difficulty swallowing pills (Source: health.harvard.edu). This widespread challenge can lead to delayed dosing, skipped treatments, and improper medication handling. In autoimmune diseases such as Multiple Sclerosis (MS) and Myasthenia Gravis (MG), swallowing impairment is even more prevalent and often becomes a decisive factor in treatment adherence and real-world therapeutic success.

In response, BioNxt has developed a proprietary rapid-dissolving, "melt-in-your-mouth" thin-film drug delivery platform and recently secured its first national-level patent, marking a major step toward commercialization in several high-value autoimmune markets.

Solving a Real Patient Problem: When Pills Are Hard to Swallow

Dysphagia is not a minor complaint - it is a structural barrier in chronic disease management. A recent systematic review found that the pooled prevalence of dysphagia in MS patients is about 45% (Source: medrxiv.org / Journal of Clinical Neuroscience). MG patients also frequently report swallowing difficulty as one of their most burdensome symptoms, with multiple studies highlighting dysphagia as a key clinical feature of the disease.

These challenges occur in disease areas representing multi-billion-dollar global markets. For example, the global MS drugs market is forecast to reach around USD 40-45 billion by 2033 (Source: ihealthcareanalyst.com; valuemarketresearch.com). Recent market analyses project the global MG treatment market to grow to between USD ~2.7-4.7 billion by 2032 (Source: fortunebusinessinsights.com; grandviewresearch.com).

For these patients, large tablets present a daily physical challenge, while injectable therapies introduce additional anxiety and treatment burden. BioNxt's thin-film technology - designed to dissolve under the tongue within seconds - offers a swallow-free, needle-free alternative that aligns with the real-world needs of autoimmune patients. The water-free format allows dosing anytime and anywhere, while being designed to reduce the risk of choking associated with conventional tablets.